Aphria Inc
APHA
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $-0.33 |
| Beta | - |
| Outstanding Shares | 316,670,951 |
Return
| Return on Equity | -40.76% |
|---|---|
| Return on Assets | -21.91% |
| Return on Invested Capital | -3.66% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 15.38 |
| Price to Book Ratio | 5.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aphria Inc
CEO: Irwin Simon Relevant Senate Committees
Controls taxation, including Section 280E which heavily impacts cannabis businesses. Any tax reform or changes to federal tax policy affecting this industry would originate from or be heavily influenced by this committee.
Oversees the Farm Bill, which has historically impacted hemp and could further shape the regulatory environment for cannabis and other botanical cultivation and processing.
Regulates the FDA and NIH. This committee directly influences how medicinal botanicals, including cannabis products, are regulated, approved, or funded for research, which is paramount for Aphria's sector.
Oversees the DOJ and federal law, making it central to any federal decriminalization, legalization, or reform efforts regarding cannabis, as well as intellectual property for botanical strains.
This committee regulates the financial system, including potential federal reforms for cannabis banking access (e.g., SAFE Banking Act) which is critical for the industry's operations and capital flow. It also oversees the SEC, impacting public companies.